Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double-blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation.
Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JL. Antin JH, et al. Among authors: soiffer rj. Blood. 2002 Nov 15;100(10):3479-82. doi: 10.1182/blood-2002-03-0985. Epub 2002 Jul 18. Blood. 2002. PMID: 12393661 Free article. Clinical Trial.
Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation.
Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Wadleigh M, et al. Among authors: soiffer rj. Blood. 2003 Sep 1;102(5):1578-82. doi: 10.1182/blood-2003-01-0255. Epub 2003 May 8. Blood. 2003. PMID: 12738663 Free article.
Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study.
Marty FM, Lee SJ, Fahey MM, Alyea EP, Soiffer RJ, Antin JH, Baden LR. Marty FM, et al. Among authors: soiffer rj. Blood. 2003 Oct 15;102(8):2768-76. doi: 10.1182/blood-2003-01-0267. Epub 2003 Jul 10. Blood. 2003. PMID: 12855583 Free article.
Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation.
Cutler C, Kim HT, Hochberg E, Ho V, Alyea E, Lee SJ, Fisher DC, Miklos D, Levin J, Sonis S, Soiffer RJ, Antin JH. Cutler C, et al. Among authors: soiffer rj. Biol Blood Marrow Transplant. 2004 May;10(5):328-36. doi: 10.1016/j.bbmt.2003.12.305. Biol Blood Marrow Transplant. 2004. PMID: 15111932 Free article. Clinical Trial.
Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH. Ho VT, et al. Among authors: soiffer rj. Blood. 2004 Aug 15;104(4):1224-6. doi: 10.1182/blood-2004-01-0028. Epub 2004 Apr 27. Blood. 2004. PMID: 15113758 Free article. Clinical Trial.
369 results